Pharmacokinetics of Quinacrine Efflux from Mouse Brain via the P-glycoprotein Efflux Transporter

The lipophilic cationic compound quinacrine has been used as an antimalarial drug for over 75 years but its pharmacokinetic profile is limited. Here, we report on the pharmacokinetic properties of quinacrine in mice. Following an oral dose of 40 mg/kg/day for 30 days, quinacrine concentration in the brain of wild-type mice was maintained at a concentration of ∼1 µM. As a substrate of the P-glycoprotein (P-gp) efflux transporter, quinacrine is actively exported from the brain, preventing its accumulation to levels that may show efficacy in some disease models. In the brains of P-gp–deficient Mdr1 0/0 mice, we found quinacrine reached concentrations of ∼80 µM without any signs of acute toxicity. Additionally, we examined the distribution and metabolism of quinacrine in the wild-type and Mdr1 0/0 brains. In wild-type mice, the co-administration of cyclosporin A, a known P-gp inhibitor, resulted in a 6-fold increase in the accumulation of quinacrine in the brain. Our findings argue that the inhibition of the P-gp efflux transporter should improve the poor pharmacokinetic properties of quinacrine in the CNS.

[1]  Kevin A Roth,et al.  Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent. , 2010, Neuro-oncology.

[2]  A. Gudkov,et al.  Anti-malaria drug blocks proteotoxic stress response: Anti-cancer implications , 2009, Cell cycle.

[3]  S. Prusiner,et al.  Continuous Quinacrine Treatment Results in the Formation of Drug-Resistant Prions , 2009, PLoS pathogens.

[4]  Hui Wang,et al.  Quinacrine protects neuronal cells against heat‐induced injury , 2009, Cell biology international.

[5]  A. Komar,et al.  9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-κB and p53 pathways , 2009, Oncogene.

[6]  S. Prusiner,et al.  A γ-secretase inhibitor and quinacrine reduce prions and prevent dendritic degeneration in murine brains , 2008, Proceedings of the National Academy of Sciences.

[7]  S. Chierici,et al.  A Multimeric Quinacrine Conjugate as a Potential Inhibitor of Alzheimer's β‐Amyloid Fibril Formation , 2008, Chembiochem : a European journal of chemical biology.

[8]  A. Gudkov,et al.  Quinacrine inhibits the epidermal dendritic cell migration initiating T cell‐mediated skin inflammation , 2007, European journal of immunology.

[9]  S. Prusiner,et al.  QUINACRINE IS MAINLY METABOLIZED TO MONO-DESETHYL QUINACRINE BY CYP3A4/5 AND ITS BRAIN ACCUMULATION IS LIMITED BY P-GLYCOPROTEIN , 2006, Drug Metabolism and Disposition.

[10]  Ronen Marmorstein,et al.  Acridine derivatives activate p53 and induce tumor cell death through bax , 2005, Cancer biology & therapy.

[11]  P. Toutain,et al.  A possible pharmacological explanation for quinacrine failure to treat prion diseases: pharmacokinetic investigations in a ovine model of scrapie , 2005, British journal of pharmacology.

[12]  S. Prusiner,et al.  Pharmacokinetics of quinacrine in the treatment of prion disease , 2004, BMC infectious diseases.

[13]  M. Fromm,et al.  Importance of P-glycoprotein at blood-tissue barriers. , 2004, Trends in pharmacological sciences.

[14]  J. Benito-León,et al.  Combined quinacrine and chlorpromazine therapy in fatal familial insomnia. , 2004, Clinical neuropharmacology.

[15]  T. Iwaki,et al.  Treatment of Transmissible Spongiform Encephalopathy by Intraventricular Drug Infusion in Animal Models , 2004, Journal of Virology.

[16]  T. Tsuruo,et al.  Uptake and Efflux of Quinacrine, a Candidate for the Treatment of Prion Diseases, at the Blood-Brain Barrier , 2004, Cellular and Molecular Neurobiology.

[17]  Tatsuo Yamada,et al.  Results of Quinacrine Administration to Patients with Creutzfeldt-Jakob Disease , 2004, Dementia and Geriatric Cognitive Disorders.

[18]  E. Kessel,et al.  Quinacrine sterilization: a retrospective , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[19]  C. Masters,et al.  Quinacrine does not prolong survival in a murine Creutzfeldt‐Jakob disease model , 2002, Annals of neurology.

[20]  F E Cohen,et al.  Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  B. Caughey,et al.  Lysosomotropic Agents and Cysteine Protease Inhibitors Inhibit Scrapie-Associated Prion Protein Accumulation , 2000, Journal of virology.

[22]  H. M. Bender,et al.  Role of blood‐brain barrier P‐glycoprotein in limiting brain accumulation and sedative side‐effects of asimadoline, a peripherally acting analgaesic drug , 1999, British journal of pharmacology.

[23]  A. Schinkel,et al.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.

[24]  J. H. Beijnen,et al.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.

[25]  D. Wallace The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. , 1989, Seminars in arthritis and rheumatism.

[26]  M. Connelly,et al.  Modulation of macrophage interaction with Trypanosoma cruzi by phospholipase A2-sensitive components of the parasite membrane. , 1984, Biochemical and biophysical research communications.

[27]  J. Berman,et al.  Activity of oral drugs against Leishmania tropica in human macrophages in vitro. , 1983, The American journal of tropical medicine and hygiene.

[28]  J. Gaddum THE PHARMACOLOGICAL BASIS OF THERAPEUTICS , 1941, Nature.

[29]  W. Pardridge The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.